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ABSTRACT
Aim and Objective: Ketorolac tromethamine is used for treatment of infections including infection of joints and bones, gastroenteritis, malignant 
Otis externa, respiratory tract infections, cellulites, urinary tract infections, anthrax and it also used in treatment of community acquired pneumonia. 
Difficulty in swallowing is a common problem of all age groups, especially the elderly and pediatrics, because of physiological changes associated with 
these groups.
Methods: Pre formulation testing is an investigation of physical and chemical properties of drug substances alone and when combined with 
pharmaceutical excipients. It is the first step in the rational development of dosage form. 
Results: The present study was undertaken to formulate Ketorolac tromethamine oral dispersible tablet with three polymers namely sodium starch 
glycolate, cros carmellose sodium and in combination of three super disintegrants and by dry granulation technique. Before compression of the 
garnules physical characters such as bulk density, tappd density, angle of repose, compressibility index and hausner ratio was determined and 
tabulated. Then the granules were compressed into tablets and then evaluated.
Conclusion: It has been observed from all formulations of pre compression and post compression studies were given with in the limits of values. The 
in vitro dissolution data, F1( combination of super disintegrant) formulation was found that the drug release is best and cumulative % of drug release 
was 90.88% respectively, when compared to other formulation.
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INTRODUCTION
Recent developments in technology have presented viable alternatives 
for the patients who may have difficulty in swallowing tablets or liquids. 
Traditional tablets and capsules administered with an 8-oz glass of 
water  [1] may be inconvenient or impractical for some patients. For 
example, a very elderly patient may not be able to swallow a daily 
dose [2] of tablets. [3] Some drugs are absorbed from mouth, pharynx 
and esophagus as saliva passes down to stomach [4] An inability or 
willingness to swallow solid oral dosage forms such as tablets and 
poor taste of medicine are some of the important reasons for consumer 
dissatisfaction(5) A schizophrenic patient in the institution setting can 
hide a conventional tablet under his/her tongue to avoid daily dose of 
atypical anti psychotic(6) The amount of drug that is subjected to first 
pass metabolism is reduced as compared to standard tablets(7) Fast 
dissolving tablet is a solid dosage form that disintegrants and dissolves 
in he mouth(8) The fast dissolving tablet that can be placed in the mouth 
where it disperses rapidly before swallowing(9)
METHODS
Pre-formulation studies
Pre formulation testing is an investigation of physical and chemical 
properties of drug substances alone and when combined with 
pharmaceutical excipients. It is the first step in the rational development 
of dosage form.  
Standard curve of ketorolac tromethamine
Sodium hydroxide solution, 0.2 m
8 g of sodium hydroxide was dissolved in 1000 ml distilled water, and 
it gives 0.2 m solution.
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Fig. 1: Standard curve of ketorolac tromethamine in phosphate 
buffer (pH 6.8)
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Table 1: Standard curve of ketorolac tromethamine in 
phosphate buffer (pH 6.8)
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Standard curve of ketorolac tromethamine
Potassium dihydrogen phosphate solution
0.2M 27.218gm of potassium dihydrogen phosphate was dissolved in 
1000ml distilled water in a volumetric flask.
Sodium hydroxide solution, 0.2M
8gm of sodium hydroxide was dissolved in 1000ml distilled water and 
gives 0.2M solution
Preparation of pH6.8 buffer
Place 50.0ml of 0.2M potassium di hydrogen phosphate in a 200ml 
volumetric flask add 22.4ml sodium hydroxide and then make up with 
water upto volume.
This is standard curve of Ketorolac tromethamine phosphate buffer with 
absorbance 290nM and linear absorbance 290nM. Its showing in Fig 1.
The disintegration time (D.T) of all formulations is shown in the Fig 2.
100mg of pure drug of ketorolac tromethamine was dissolved in 10ml 
volumetric flask and shaked with 5ml methanol. for the above solution 
add remaining amount was make up with 6.8pH Phosphate buffer .This 
solution contains 1000µg/ml of ketorolac tromethamine stock solution. 
Take 10ml from above solution in 100ml volumetric flask and make up 
with 6.8pH phosphate buffer. This solution contains 100µg/ml of drug. 
From above solution take 1ml in 10ml volumetric flask and make up 
with 6.8pH phosphate buffer. From this solution pipette out 0.2ml in 
10ml volumetric flask add buffer. This gives0.2µg/ml solution. Similarly Fig. 3: Wetting time
Fig.4: FTIR spectrum of ketorolac tromethamine.
Table 2: Different formulation of ketorolac tromethamine oral dispersible tablets
S. No. Formulation code Drug SSG CCS Mannitol Sodium saccharin Magnesium stearate Mint flavor
1. F1 10 5 - 78 5 2 q. s
2. F2 10 10 - 73 5 2 q. s
3. F3 10 - 5 78 5 2 q. s
4. F4 10 - 10 73 5 2 q. s
5. F5 10 5 5 73 5 2 q. s
CCS: Croscarmellose sodium, SSG: Sodium starch glycolate
Fig. 2: Disintegration time
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Fig. 5: FTIR Spectrum of Sodium starch glycolate
Table 3: Pre-compression studies of powder blend










1. F1 2.35 0.35 0.154 99.5 98.22
2. F2 2.44 0.35 0.218 99.7 96.39
3. F3 3.52 0.35 0.256 99.8 97.64
4. F4 2.82 0.35 0.277 99.7 97.57
5. F5 2.75 0.35 0.234 99.7 95.48
Table 4: Pre compression studies of Powder blend










1. F1 0.384 0.385 31.26 10.73 1.322
2. F2 0.356 0.362 35.15 6.58 1.175
3. F3 0.358 0.372 32.82 9.29 1.203
4. F4 0.382 0.323 32.38 6.10 1.167
5. F5 0.343 0.358 34.07 9.21 1.005
preparing 0.4ml, 0.6ml, 0.8ml and 1ml of solution in 10ml volumetric 
flasks. Resulting gives 2µg/ml ,4µg/ml ,6µg/ml,
8 µg/ml and 10µg/ml  solutions. The concentrated solution scanned 
in UV-Visible Spectrophotometer meter with absorption maimum is 
290nm shown in Table 1.
In this method, all the powder excipients are mixed thoroughly in a 
polyethylene bag. After proper mixing the powder was punched into 
tablets. The weight of the tablet was 400mg and dose of the drug is 
150mg. Each tablet weight- 100mg shown in Table 2.
The compressed tablets were evaluated for physical properties and the 
results are tabulated for Hardness test, Thickness test, Friability test, % of 
weight variation test and Estimation of drug content values showed in Table 3.
Method of preparation
Preparation of ketorolac tromethamine tablets
Direct compression technique
Each tablet wetting time (WT) - 100 mg.





h=Height of the powder cone,
r=Radius of the powder cone.
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Fig. 7: Formulation-1 (F1)
Fig. 8: Formulation-2 (F2)
Table 5: Post‑compression studies of ketorolac tromethamine 
oral dispersible tablets
S. No. Formulations Disintegration time (s) WT (s)
1. F1 24 16
2. F2 22 17
3. F3 30 18
4. F4 21 16
5. F5 25 16
WT: Wetting time
Table 6: FTIR spectrum of ketorolac tromethamine.
S. No. Wave number Functional group
1. 3442 OH stretching carboxylic acid
2. 3129 =CH aromatic heterocyclic stretching
3. 3067 =CH aromatic stretching
4. 2966 alkyl stretching
5. 1226 C-N stretching
6. 1454 Alkyl CH2 bending
7. 1384 Alkyl CH2 bending
8. 899 CH- aromatic bending
9. 1700 C = O stretching
10. 1384 C-OH bending
FTIR: Fourier-transform infrared spectroscopy
Table 7: FTIR Spectrum of Sodium starch glycolate
S. No. Wave number Functional group
1. 3409 OH stretching
2. 2928 alkyl CH stretching
3. 1602 COO anti-symmetry stretching
4. 1239 C-O-C stretching
FTIR: Fourier-transform infrared spectroscopy, SSG: Sodium starch glycolate
Fig. 6: FTIR Spectrum of ketorolac tromethamine and sodium starch glycolate
RESULTS AND DISCUSSIONS
Pre-formulation studies
The present study was undertaken to formulate Ketorolac 
tromethamine oral dispersible tablet with three polymers namely 
sodium starch glycolate, cros carmellose sodium and in combination 
of three super disintegrants and by dry granulation technique. Before 
compression of the granules physical characters such as bulk density, 
tapped density, angle of repose, compressibility index and hausner ratio 
was determined and tabulated. Then the granules were compressed 
into tablets and then evaluated.
167
Asian J Pharm Clin Res, Vol 11, Special Issue 4, 2018, 163-169
 Sangeetha et al. 
Table 8:FTIR Spectrum of ketorolac tromethamine and sodium 
starch glycolate
S. No. Wave number Functional group
1. 3350 OH stretching
2. 3105 =CH aromatic heterocyclic ring
3. 2922 alkyl CH stretching
FTIR: Fourier-transform infrared spectroscopy, SSG: Sodium starch glycolate
Table 9: Formulations-1 (F1)
S. No. Time (min) Absorbance (290 nm) Concentration (µg/ml) Amount of drug release (in 900 ml) % of drug release
1. 0 0.000 0.000 0.000 0.000
2. 1 0.128 1.068 9.810 6.49
3. 3 0.498 4.354 39.85 26.67
4. 6 0.687 6.010 54.20 36.55
5. 9 0.922 8.056 72.66 48.77
6. 12 1.243 10.976 98.68 65.78
7. 15 1.724 15.184 136.01 90.88
SSG: Sodium starch glycolate
Table 10: Formulations-2 (F2)
S. No. Time (min) Absorbance (290 nm) Concentration (µg/ml) Amount of drug release (in 900 ml) % of drug release
1. 0 0.000 0.000 0.000 0.000
2. 1 0.076 0.852 7.598 5.25
3. 3 0.382 3.478 30.84 20.73
4. 6 0.568 5.172 46.43 31.85
5. 9 0.878 7.73 69.89 46.36
6. 12 1.162 10.30 90.74 60.83
7. 15 1.654 14.88 132.89 88.30
Table 11: Formulations-3 (F3)
S. No. Time (min) Absorbance (290 nm) Concentration (µg/ml) Amount of drug release (in 900 ml) % of drug release
1 0 0.000 0.000 0.000 0.000
2 1 0.072 0.779 6.493 4.325
3 3 0.384 3.182 28.53 19.35
4 6 0.582 4.689 44.86 29.67
5 9 0.863 7.472 67.54 44.99
6 12 1.116 9.601 87.81 58.71
7 15 1.593 13.98 124.7 83.81
Table 12: Formulations-4 (F4)
S. No. Time (min) Absorbance (290 nm) Concentration  µg/ml) Amount of drug release (in 900 ml) % of drug release
1. 0 0.000 0.000 0.000 0.000
2. 1 0.108 0.947 8.526 5.684
3. 3 0.405 3.552 31.97 21.31
4. 6 0.612 5.368 48.31 32.21
5. 9 0.894 7.842 70.57 47.05
6. 12 1.168 10.24 92.21 61.47
7. 15 1.686 14.78 133.1 88.73
Table 13: Formulations-5 (F5)
S. No. Time (min) Absorbance (290 nm) Concentration (µg/ml) Amount of drug release (in 900 ml) % of drug release
1. 0 0.000 0.000 0.000 0.000
2. 1 0.108 0.947 8.526 5.684
3. 3 0.405 3.552 31.97 21.31
4. 6 0.612 5.368 48.31 32.21
5. 9 0.894 7.842 70.57 47.05
6. 12 1.168 10.24 92.21 61.47
7. 15 1.686 14.78 133.1 88.73
WT study
The WT of all formulations is shown in Table 5 and Fig. 3.
The disintegration time (D.T) of all formulations is shown in the Table 5.
The IR Spectral studies of pure ketorolac tromethamine were carried 
out to study the interaction between the drug and super disintegrants 
used. It showed that IR spectrum of pure drug ketorolac tromethamine 
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and super disintegrants were similar fundamental peaks and patterns. 
The results proved that there were no significant interactions between 
the drug and super disintegrants. The results are shown in Table 6 and 
Fig 4. 
The IR Spectral studies of  sodium starch glycolate  were carried out to 
study the interaction between the drug and super disintegrants used. 
It showed that IR spectrum of pure drug ketorolac tromethamine and 
super disintegrants were similar fundamental peaks and patterns. The 
results proved that there were no significant interactions between the 
drug and super disintegrants. The results are shown in Table 7 and 
Fig 5.
The IR Spectral studies of pure ketorolac tromethamine, sodium starch 
glycolate were carried out to study the interaction between the drug 
and super dis integrants used. It showed that IR spectrum of pure 
drug ketorolac tromethamine and super disintegrants were similar 
fundamental peaks and patterns. The results proved that there were no 
significant interactions between the drug and super disintegrants. The 
results are shown in Table 8 and Fig 6.
The in vitro drug release profile of tablets from formulation 1 batch was 
carried in phosphate buffer (pH 6.8) for 15mts by using paddle type of 
device. From the in vitro dissolution data, F1 formulation was found 
that that drug release and cumulative % of drug release was 90.88% 
respectively shown in Fig 7.
The in vitro drug release profile of tablets from formulation 2 batch was 
carried in phosphate buffer (pH 6.8) for 15mts by using paddle type of 
device. From the in vitro dissolution data, F2 formulation was found 
that that drug release and cumulative % of drug release was 88.3% 
respectively shown in Fig 8. 
The in vitro drug release profile of tablets from formulation 3 batch was 
carried in phosphate buffer (pH 6.8) for 15mts by using paddle type of 
device. From the in vitro dissolution data, F3 formulation was found 
that that drug release and cumulative % of drug release was 83.81% 
respectively shown in Fig 9. 
The in vitro drug release profile of tablets from formulation 4 batch was 
carried in phosphate buffer (pH 6.8) for 15mts by using paddle type of 
device. From the in vitro dissolution data, F4 formulation was found 
that that drug release and cumulative % of drug release was 92.78% 
respectively shown in Fig 10.   
The in vitro drug release profile of tablets from formulation 5 batch was 
carried in phosphate buffer (pH 6.8) for 15mts by using paddle type of 
device. From the in vitro dissolution data, F5 formulation was found 
that that drug release and cumulative % of drug release was 88.73% 
respectively shown in Fig 11. 
The in vitro drug release profile of tablets from each batch (F1 to F5) was 
carried in phosphate buffer (pH 6.8) for 15mts by using paddle type of 
device. From the in vitro dissolution data, F1 formulation was found that 
that drug release is best and cumulative % of drug release was 90.88% 
respectively, when compared to other formulations. shown in Fig 12.    
In vitro drug release study
Tablets of all the formulations were subjected for in vitro release 
studies. The results are presented in Tables 9-14.
The present study was undertaken to formulate Ketorolac 
tromethamine oral dispersible tablet with three polymers namely 
sodium starch glycolate, cros carmellose sodium and in combination 
of three super disintegrants and by dry granulation technique. Before 
compression of the granules physical characters such as bulk density, 
tapped density, angle of repose, compressibility index and hausner ratio 
was determined and tabulated in Table 12.
DISCUSSION
Oral dispersible tablets of ketorolac tromethamine were prepared by 
direct compression method. Microscopic examination of tablets from 
each formulation batch showed circular result.
Fig. 10: Formulation-4 (F4)
Fig. 11: Formulation-5 (F5)
Table 14: Comparative dissolution study of different formulations with various ratios of super disintegrants
S. No. Time (min) % of drug release (F1) % of drug release (F2) % of drug release (F3) % of drug release (F4) % of drug release (F5)
1. 0 0.000 0.000 0.000 0.000 0.000
2. 1 6.49 5.25 4.325 6.947 5.684
3. 3 26.67 20.73 19.35 27.42 21.31
4. 6 36.55 31.85 29.67 36.52 32.21
5. 9 48.77 46.36 44.99 49.57 47.05
6. 12 65.78 60.83 58.71 66.10 61.47
7. 15 90.88 88.30 83.81 92.78 88.73
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Fig. 12: Comparative dissolution study of different formulations with various ratios of super disintegrants
CONCLUSION
It has been observed from all formulations of pre compression and post 
compression studies were given with in the limits of values. The in vitro 
dissolution data, F1( combination of super disintegrant) formulation 
was found that the drug release is best and cumulative % of drug 
release was 90.88% respectively, when compared to other formulation. 
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